Macromolecular Conjugates of Methotrexate, Ferrocene and Platinum in Cancer Chemotherapy

Mufula, Alain I.; Neuse, Eberhard W.

doi:10.1007/s10904-011-9497-3

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…127 Many of the strategies applied to platinum drugs have been translated to organometallic systems, with ferrocene-containing polymers being perhaps the most extensively studied. 128 Relatively small dendrimer systems decorated with ruthenium(II)−arene fragments have been reported and a correlation between size and cytotoxicity observed. 129 Remarkably, recombinant human serum albumin (rHSA) derivatized with noncytotoxic Ru(η 6 -arene)(pta)Cl 2 complexes (typically four per rHSA), via a pH-cleavable linker, dramatically increased accumulation of the metal within cancer cells, resulting in considerably greater antiproliferative activity in comparison to that of Ru(η 6 -arene)(pta)Cl 2 complexes alone.…”

Section: ■ Metal−carbenes and Other Ligand Typesmentioning

confidence: 99%

“…Passive targeting of macromolecules to the tumor environment is possible due to their enhanced vascular permeability that is not present in the healthy endothelial layer surrounding the blood vessels feeding healthy tissue . Many of the strategies applied to platinum drugs have been translated to organometallic systems, with ferrocene-containing polymers being perhaps the most extensively studied …”

Section: Polynuclear Complexes Clusters and Macromoleculesmentioning

confidence: 99%

See 1 more Smart Citation

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

2012

View full text Add to dashboard Cite

This review provides an introduction into the fascinating area of organometallic anticancer compounds. Although the subject dates back many years, it has witnessed considerable growth only in the past decade. A brief overview of the subject together with recent pertinent examples is provided. The properties of organometallic compounds that lend themselves to medical applications, the main current approaches used, and possible avenues for future research are identified.

show abstract

Section: ■ Metal−carbenes and Other Ligand Typesmentioning

confidence: 99%

Section: Polynuclear Complexes Clusters and Macromoleculesmentioning

confidence: 99%

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

2012

View full text Add to dashboard Cite

show abstract

“…34,35 In addition, vesicular structures like liposomes with covalently bound ferrocenyl groups are available as well, which are important in the design of redox-sensitive liposome or carrier polymer delivery systems from which the bioactive compound may be released in the intracellular space. 22,33…”

Section: Unsupported Polymer Networkmentioning

confidence: 99%

Polymers with pendant ferrocenes

2016

View full text Add to dashboard Cite

The tailoring of smart material properties is one of the challenges in materials science. The unique features of polymers with pendant ferrocene units, either as ferrocenyl or ferrocenediyl groups, provide electrochemical, electronic, optoelectronic, catalytic, and biological properties with potential for applications as smart materials. The possibility to tune or to switch the properties of such materials relies mostly on the redox activity of the ferrocene/ferricenium couple. By switching the redox state of ferrocenyl units - separately or in a cooperative fashion - charge, polarity, color (UV-vis range) and hydrophilicity of polymers, polymer functionalized surfaces and polymer derived networks (sol-gel) may be controlled. In turn, also the vicinity of such polymers influences the redox behavior of the pendant ferrocenyl units allowing for sensing applications by using polymer bound enzymes as triggering units. In this review the focus is set mainly on the literature of the past five years.

show abstract

“…The first step leading to formation of homoconjugate [11] with about 50% -NH 2 acylation, was HBTU-mediated. It involved the treatment of the selected carriers with 1.2-1.3 equivalents of the first drug (MTX or folic acid) and 1.1 equivalent of HBTU.…”

Section: Resultsmentioning

confidence: 99%

Macromolecular Co-Conjugates of Methotrexate and Ferrocene in the Chemotherapy of Cancer

Mufula

Aderibigbe

Neuse

et al. 2011

J Inorg Organomet Polym

Self Cite

View full text Add to dashboard Cite

Novel anticancer ''as reported by Neuse (Synthetic Polymers as Drug-Delivery Vehicles in Medicine, Hindawi Publishing Corporation, Cairo, 2008) and Mufula (Macromolecular Derivatives of Methotrexate and Ferrocene as Potential Prodrugs in Cancer Chemotherapy, MSc. Dissertation, School of Chemistry, Wits University, Cambridge, 2010)'' drugs with enhanced therapeutic effectiveness were synthesized through the concept of drug co-conjugation with polymer carriers. The expected benefits are synergistic effects, which can potentially lead to reduction in doses and side effects caused by high dose of single drug, and the prevention of the development of multi-drug resistance. Multidrug-binding ability of polyaspartamide-type carriers was demonstrated by the coconjugation with ferrocene and methotrexate (MTX) to the polymer carriers as well as the co-conjugation of ferrocene and folic acid in a two step process involving the HBTU coupling method. The degree of MTX incorporated was found in the range of 10-19% by mass and the degree of Fe found was in the range of 6-13% by mass for the first step of coupling. The degrees MTX, Fe and FA were found to be in the range of 17-27%, 15-16% and 24-26% respectively for the second step.

show abstract

Macromolecular Conjugates of Methotrexate, Ferrocene and Platinum in Cancer Chemotherapy

Cited by 8 publications

References 17 publications

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

Polymers with pendant ferrocenes

Macromolecular Co-Conjugates of Methotrexate and Ferrocene in the Chemotherapy of Cancer

Contact Info

Product

Resources

About